Global Bipolar Disorder Therapeutic Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Bipolar Disorder Therapeutic Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Bipolar disorder, also known as manic-depressive disorder, is a mental illness. It is a mental health problem that primarily affects mood. Symptoms of bipolar disorder are extreme irritability or agitation, a period of feeling empty, loss of interest in normal activities, sleep problems, etc. According to Pfizer, Inc., bipolar disorder affects over 5 million people in the U.S. Bipolar episodes are characterized by a drastic change in behavior and mood, and range from joyful and overexcited (manic episodes) to extremely sad and hopeless (depressive state). These disorders have different types of episodes such as manic episodes, hypomanic episodes, depressive episodes, and mixed episodes. Causes of bipolar disorders include childhood trauma, stressful life events, self-esteem problems, and genetic inheritance. People across the world marked “March 30” as a World Bipolar Day to spread awareness about the disorder and erase the stigma of mental illness. Large number of people suffering from this mental condition resort to drinking to lift their mood. According to the National Institute on Alcohol Abuse and Alcoholism, 27.6% of the people with bipolar disorder become addicted to alcohol, while over 16% engaged in alcohol abuse.
Bipolar Disorder Therapeutic report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Bipolar Disorder Therapeutic market is projected to reach US$ 4443.3 million in 2034, increasing from US$ 3855.3 million in 2022, with the CAGR of 2.0% during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
The growing need to reduce the financial burden of bipolar disorder will drive the growth prospects for the global bipolar disorder therapeutic market until the end of 2021. It has been observed that governments and companies across the globe are increasingly organizing awareness camps to raise disease awareness among the public, reduce the burden of mental disorders in vulnerable groups, ensure the rights of people with mental disorders, and make treatment facilities accessible to them. Consequently, such awareness initiatives help to curb the overall monetary loss, reduce their effect on the global economy, and improve the quality of life for patients. Such factors will raise public awareness about mental disorders and treatments and in turn, propel the rate of revenue generation in the market.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Bipolar Disorder Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Eli Lilly
Bristol-Myers Squibb
AstraZeneca
Allergan
Astellas Pharma
GlaxoSmithKline
Janssen Pharmaceuticals
Segment by Type
Antipsychotics
Anticonvulsants
Mood Stabilizers
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Bipolar Disorder Therapeutic market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Bipolar Disorder Therapeutic, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Bipolar Disorder Therapeutic industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Bipolar Disorder Therapeutic in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Bipolar Disorder Therapeutic introduction, etc. Bipolar Disorder Therapeutic Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Bipolar Disorder Therapeutic market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Bipolar Disorder Therapeutic report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Bipolar Disorder Therapeutic market is projected to reach US$ 4443.3 million in 2034, increasing from US$ 3855.3 million in 2022, with the CAGR of 2.0% during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
The growing need to reduce the financial burden of bipolar disorder will drive the growth prospects for the global bipolar disorder therapeutic market until the end of 2021. It has been observed that governments and companies across the globe are increasingly organizing awareness camps to raise disease awareness among the public, reduce the burden of mental disorders in vulnerable groups, ensure the rights of people with mental disorders, and make treatment facilities accessible to them. Consequently, such awareness initiatives help to curb the overall monetary loss, reduce their effect on the global economy, and improve the quality of life for patients. Such factors will raise public awareness about mental disorders and treatments and in turn, propel the rate of revenue generation in the market.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Bipolar Disorder Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Eli Lilly
Bristol-Myers Squibb
AstraZeneca
Allergan
Astellas Pharma
GlaxoSmithKline
Janssen Pharmaceuticals
Segment by Type
Antipsychotics
Anticonvulsants
Mood Stabilizers
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Bipolar Disorder Therapeutic market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Bipolar Disorder Therapeutic, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Bipolar Disorder Therapeutic industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Bipolar Disorder Therapeutic in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Bipolar Disorder Therapeutic introduction, etc. Bipolar Disorder Therapeutic Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Bipolar Disorder Therapeutic market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices